SLC8A1 inhibitors have been proposed as a therapeutic target for HF as SAR340835-treated HF dogs showed an improved stroke volume and sympathovagal balance (Pelat et al, 2021). The gene discussed is SLC8A1; the disease is hydrops fetalis.